Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

We recently published a list of Jim Cramer’s Take on These 10 Stocks. In this article, we are going to take a look at where ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Eli Lilly’s stock slipped during a broader market nosedive sparked by Trump’s tariff barrage, but retail traders oddly found ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 ...

Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to ...

The stock's fall snapped a two-day winning streak.

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...